The FieldForce system provides a new method for creating transmural lesions in VT ablation. Credit: Field Medical / PRNewswire.

Field Medical has closed a $35m series B financing round for advancing the development of the FieldForce pulsed field ablation platform.

This round was co-led by BioStar Capital and Cue Growth, with contributions from current strategic investors.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The funds will also facilitate the launch of the pivotal VERITAS trial and strengthen the company’s clinical and regulatory capabilities. It brings Field Medical’s total funding to $75m.

BioStar Capital founder and senior managing director Dr Louis Cannon said: “Field Medical’s transformative technology is doing what few companies dare to do – tackling one of the most difficult and under-addressed challenges in cardiology with real innovation and urgency.

“Their physician-led team brings the right insight, and their FieldForce platform brings the right tools.”

In 2024, the FieldForce ablation system received breakthrough device designation and was selected for the US Food and Drug Administration (FDA) TAP Pilot programme for ventricular tachycardia (VT).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The next-generation system has been designed for transmural lesion creation and provides a new approach to VT ablation.

It remains an investigational device, limited to research use under US law.

Field Medical founder and CEO Dr Steven Mickelsen said: “VT is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need.

“We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.”

In conjunction with this growth funding, Field Medical has updated its board of directors.

The board includes Dr Steven Mickelsen, the company’s founder and CEO; Mark Wisniewski, CFO of Enterra Medical; and Marlou Janssen, board member at Field Medical, Sonion, Acarix, EBAMed and Inspiration Healthcare.

Additional members comprise surgeon and entrepreneur Alexei Mlodinow and Cue Growth founding partner Ben Cannon.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact